Committee Leaves The Door Open For Lundbeck’s Schizophrenia Drug Serdolect

Advisory panel was clear that there is a cardiovascular risk, but suggested there may be a way to define a subpopulation that can benefit.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet